Recce Pharmaceuticals highlights US$66.9B biodefence strategy

·       Recce highlighted the United States government's five-year, US$66.9 billion funding strategy targeting pandemics and drug-resistant superbugs.

·       The company share price was down at $0.37 following the announcement.

·       The company stated that the funding strategy aligns with its ongoing development of broad-spectrum antimicrobials.

Recce Pharmaceuticals (ASX:RCE) highlighted the release of a five-year, US$66.9 billion medical countermeasures funding strategy by the United States Department of Health and Human Services.

The strategy follows prior federal health planning efforts and places a heightened focus on antimicrobial resistance as a top national security priority.

The company did not include an executive quote in its announcement release.

The funding framework allocates US$4.46 billion specifically for broad-spectrum antimicrobials, which ranks as the second-highest single-threat funding priority behind pandemic influenza.

The company stated that the initiative aims to advance antimicrobial candidates through clinical trials and regulatory approval stages.

Following the announcement, the Recce Pharmaceuticals share price was down at $0.37.

Recce focuses on the development of synthetic anti-infectives designed to address antibiotic-resistant superbugs through ongoing research programmes.

The business maintains active research collaborations, including two cooperative research and development agreements with the United States Army alongside related grant support.